Endometrial carcinoma from the standpoint of pathology: Current developments and perspectives

The well-established four molecular subtypes (POLEmut, MMRd, NSMP, and P53abn) of endometrial carcinoma are today considered together with conventional morphological parameters in unified risk classifications. The clinical–therapeutic relevance lies especially in de-escalating concepts to avoid adjuvant therapies without benefit for POLEmut carcinomas. In more advanced stages, however, testing for checkpoint inhibition and anti-Her2 therapy might be considered. The aim of this review is to provide background information and suggestions for the practical implementation in clinical routine. © 2023, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.